Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol

American Journal of Cardiology

Volumn 92, Issue 5, 2003, Pages 538-543

  Bays, Harold E ^a   McKenney, James M ^b   Dujovne, Carlos A ^b   Schrott, Helmut G ^b   Zema, Michael J ^b   Nyberg, Jack ^b   MacDougall, Diane E ^b  

^a Louisville Metab Atherosclerosis R   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL ETHER; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; GEMCABENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GALLBLADDER DISEASE; HUMAN; MALE; PAIN; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0043011486     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00721-5     Document Type: Article

References (7)

1. Bisgaier C.L., Essenburg A.D., Barnett B.C., Auerbach B.J., Haubenwallner S., Leff T., White A.D., Creger P., Pape M.E., Rea T.J., Newton R.S. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res. 39:1998;17-30.
2. NCEP Expert Panel. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda, MD: National Institute of Health Publication No. 01-3670, May 2001.
3. Freidewald W.T., Levy R.I., Frederickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without using preparative ultra-centrifuge. Clin Chem. 18:1972;499-522.
4. Shapiro S.S., Wilk M.B. An analysis of variance test for normality (complete samples). Biometrika. 52:1965;591-611.
5. Bays H.E. Existing, and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol. 90:(suppl):2002;30K-43K.
6. Cui Y., Blumenthal R.S., Flaws J.A., Whiteman M.K., Langenberg P., Bachorik P.S., Bush T.L. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 161:2001;1413-1419.
7. Frost P.H., Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 81:(suppl):1998;26B-31B.